Azevan Pharmaceuticals
Innovative therapies for stress, mood, and behavior disorders
Innovative therapies for stress, mood, and behavior disorders
Azevan Pharmaceuticals is a clinical stage company focused on developing small molecule drugs to treat disorders related to stress, mood, and behavior. With a dedication to inhibiting the effects of arginine vasopressin, a peptide neurohormone associated with conditions such as major depression, intermittent explosive disorder, impulse control and anger disorders, as well as post-traumatic stress disorder (PTSD), the company aims to address unmet needs in mental health. Their product offerings, SRX251 and SRX246, are CNS-penetrating V1a receptor antagonists designed for oral administration, targeting stress-related CNS disorders including depression, PTSD, and intermittent explosive disorders. Formerly known as Serenix Pharmaceuticals, LLC, the company rebranded to Azevan Pharmaceuticals, Inc. in January 2002 and was founded in 1999. The company secured a $2.21M Venture Round investment on 18 October 2013 to further its innovative therapies. Headquartered in Bethlehem, Pennsylvania, Azevan Pharmaceuticals operates within the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.21M | - | 18 Oct 2013 |
No recent news or press coverage available for Azevan Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
